Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs Transplantation for Parkinson's Disease
NCT03550183Phase 1Unknown
- Sponsor
- Hebei Newtherapy Bio-Pharma Technology Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Oct 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human umbilical cord mesenchymal stem cells in Parkinson's disease (PD) (2 arms), sponsored by Hebei Newtherapy Bio-Pharma Technology Co., Ltd. Primary endpoint: Unified Parkinson's Disease Rating Scale at 12 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03550183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03550183.